Similar articles

• 'Biosimilar' drugs poised to penetrate market.

  Ledford H. Ledford H. Nature. 2010 Nov 4;468(7320):18-9. doi: 10.1038/468018a. Nature. 2010. PMID: 21048737 No abstract available.
• Biotech industry struggles with generics approval.

  Knight J. Knight J. Nature. 2004 Jun 10;429(6992):588. doi: 10.1038/429588b. Nature. 2004. PMID: 15190316 No abstract available.
• Current regulatory and legal considerations for follow-on biologics.

  Kingham RF, Lietzan E. Kingham RF, et al. Clin Pharmacol Ther. 2008 Nov;84(5):633-5. doi: 10.1038/clpt.2008.159. Epub 2008 Aug 20. Clin Pharmacol Ther. 2008. PMID: 18716615 No abstract available.
• Follow-on biologics: data exclusivity and the balance between innovation and competition.

  Grabowski H. Grabowski H. Nat Rev Drug Discov. 2008 Jun;7(6):479-88. doi: 10.1038/nrd2532. Epub 2008 May 12. Nat Rev Drug Discov. 2008. PMID: 18469828 Review.
• Generic drug approval: a US perspective.

  Nagori BP, Mathur V, Garg S. Nagori BP, et al. Curr Med Res Opin. 2011 Mar;27(3):541-5. doi: 10.1185/03007995.2010.548374. Epub 2011 Jan 10. Curr Med Res Opin. 2011. PMID: 21219120 Review.